Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population
BACKGROUND There is little information about weight gain induced by antipsychotics at long-term . OBJECTIVE To quantify the weight gain induced by first ( haloperidol ) and second generation antipsychotics ( olanzapine and risperidone ) in a cohort of drug-naïve subjects after 1 year of treatment . METHODS This is a prospect i ve , r and omized clinical trial , including a representative sample of first episode psychotic incident cases from a population area of 555.000 people . The main outcome measures were changes in body weight and body mass index at 3 months and at 12 months . Both a per protocol analysis and an intention to treat analysis were conducted . RESULTS A total of 164 drug-naïve patients were included . At 12 months 144 patients were evaluated . Of them , 66 % completed the protocol and 34 % needed treatment switch . We found statistically significant differences in weight gain at 3 months : 3.8 kg ( + /-4.1 ) for haloperidol , 5.9 kg ( + /-5.1 ) for risperidone and 8.4 kg ( + /-5.0 ) for olanzapine ( F=7.045 ; p=0.002 ) . After 1 year the difference in weight gain had disappeared : 9.7 kg ( + /-5.7 ) for haloperidol , 8.9 kg ( + /-8.8 ) for risperidone and 10.9 kg ( + /-7.2 ) for olanzapine ( F=0.817 ; p=0.445 ) . CONCLUSIONS Drug-naïve patients experience an extraordinary weight gain after 1 year of treatment with haloperidol , olanzapine or risperidone . The main difference among these treatments is the pattern of weight gain but not the final amount of weight gain
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .